STOP AF FIRST
M
Mithilesh Das
Primary Investigator
Overview
The purpose is to provide data demonstrating the safety and effectiveness of the Arctic Front Advance Cardiac CryoAblation Catheter for the treatment of recurrent symptomatic paroxysmal AF, without the requirement that the subjects be drug refractory.
Description
The purpose is to provide data demonstrating the safety and effectiveness of the Arctic Front Advance Cardiac CryoAblation Catheter for the treatment of recurrent symptomatic paroxysmal AF, without the requirement that the subjects be drug refractory.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
atrial fibrillation
-
Age: Between 18 Years - 80 Years
-
Gender: All
Inclusion Criteria
Were diagnosed with symptomatic paroxysmal AF
Have not taken any Class I or III antiarrhythmic drug
Have not taken any Class I or III antiarrhythmic drug
Updated on
25 Apr 2024.
Study ID: 1706971444
